- Home
- EOLS vs FBIOP Comparison
EOLS vs FBIOP Comparison
Compare EOLS & FBIOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOLS
- FBIOP
- Stock Information
- Founded
- EOLS 2012
- FBIOP N/A
- Country
- EOLS United States
- FBIOP United States
- Employees
- EOLS N/A
- FBIOP 101
- Industry
- EOLS Biotechnology: Pharmaceutical Preparations
- FBIOP Biotechnology: Pharmaceutical Preparations
- Sector
- EOLS Health Care
- FBIOP Health Care
- Exchange
- EOLS Nasdaq
- FBIOP Nasdaq
- Market Cap
- EOLS N/A
- FBIOP N/A
- IPO Year
- EOLS 2018
- FBIOP N/A
- Fundamental
- Price
- EOLS $10.01
- FBIOP $7.76
- Analyst Decision
- EOLS Strong Buy
- FBIOP
- Analyst Count
- EOLS 5
- FBIOP 0
- Target Price
- EOLS $23.75
- FBIOP N/A
- AVG Volume (30 Days)
- EOLS 1.2M
- FBIOP N/A
- Earning Date
- EOLS 05-07-2025
- FBIOP N/A
- Dividend Yield
- EOLS N/A
- FBIOP N/A
- EPS Growth
- EOLS N/A
- FBIOP N/A
- EPS
- EOLS N/A
- FBIOP N/A
- Revenue
- EOLS $275,463,000.00
- FBIOP N/A
- Revenue This Year
- EOLS $33.27
- FBIOP N/A
- Revenue Next Year
- EOLS $32.31
- FBIOP N/A
- P/E Ratio
- EOLS N/A
- FBIOP N/A
- Revenue Growth
- EOLS 25.38
- FBIOP N/A
- 52 Week Low
- EOLS $8.67
- FBIOP N/A
- 52 Week High
- EOLS $17.82
- FBIOP N/A
- Technical
- Relative Strength Index (RSI)
- EOLS 38.96
- FBIOP 75.47
- Support Level
- EOLS $8.75
- FBIOP $6.43
- Resistance Level
- EOLS $9.67
- FBIOP $7.00
- Average True Range (ATR)
- EOLS 0.47
- FBIOP 0.35
- MACD
- EOLS -0.03
- FBIOP 0.13
- Stochastic Oscillator
- EOLS 36.86
- FBIOP 100.00
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.